Unlock instant, AI-driven research and patent intelligence for your innovation.
Metalloprotease inhibitors containing a heterocyclic moiety
Inactive Publication Date: 2008-09-11
ALANTOS PHARMA HLDG INC
View PDF1 Cites 20 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Benefits of technology
[0016]In particular, the heterocyclic metalloprotease inhibiting compounds of the present invention may be used in the treatment of MMP-13, MMP-8 and MMP-3 mediated degenerative diseases characterized by excessive extracellular matrix degradation and/or remodelling, such as cancer, and chronic inflammatory diseases such as arthritis, rheumatoid arthritis, osteoarthritis, atherosclerosis, abdominal aortic aneurysm, inflammation, multiple sclerosis, parkinsons disease, chronic obstructive pulmonary disease and pain, such as inflammatory pain, bone pain and joint pain.
[0017]The present invention also provides heterocyclic metalloprotease inhibiting compounds that are useful as active ingredients in pharmaceutical compositions for treatment or prevention of metalloprotease—especially MMP-13—mediated diseases. The present invention also contemplates use of such compounds in pharmaceutical compositions for oral or parenteral administration, comprising one or more of the heterocyclic metalloprotease inhibiting compounds disclosed herein.
[0018]The present invention further provides methods of inhibiting metalloproteases, by administering formulations, including, but not limited to, oral, rectal, topical, intravenous, parenteral (including, but not
Problems solved by technology
The difficulty in developing effective MMP inhibiting compounds comprises several factors, including choice of selective versus broad-spectrum MMP inhibitors and rendering such compounds bioavailable via an oral route of administration.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
examples 3a to 3b
Preparative Examples 3a to 3b
[0138]Following a similar procedure as described in the Preparative Example 3, except using the aminoalcohols indicated in Table 1.3 below, the following compounds were prepared.
[0140]A suspension of the title compound from the Preparative Example 3, Step B (567 mg) and CuCN (230 mg) in dry N-methyl-pyrrolidin-2-one (15 mL) was degassed under Argon and heated under microwaveirradiation to 200° C. for 2 h. The mixture was concentrated, diluted with 1N HCl (100 mL) and extracted with EtOAc (200 mL). The organic layers were washed with H2O (2×200 mL) and brine (200 mL), dried (MgSO4), filtered, absorbed on silica and purified by flash chromatography (cyclohexane / ethyl acetate 7:3 to 6:5) to give the title compound as a colourless solid. [MH]+=211.
Step B
[0141]To an ice cooled solution of the title compound from Step A above in dry MeOH (20 mL) were added di-tert-butyl dicarbonate (500 mg) and NiCl2.6H2O (20 mg), followed by the careful portionwise addition of NaBH4 (320 mg). The resulting black mixture was stirred for 20 min at 0-5° C. (ice bath), then the ice bath was removed and stirring at room temperature was continued over...
examples 4a to 4d
Preparative Examples 4a to 4d
[0143]Following a similar procedure as described in the Preparative Example 4, Step A except using the educt indicated in Table I.4 below, the following compounds were prepared.
[0144]Following a similar procedure as described in the Preparative Example 4, Step B except using the educt indicated in Table I.5 below, the following compounds were prepared.
[0145]Following a similar procedure as described in the Preparative Example 4, Step C except using the educt indicated in Table I.6 below, the following compounds were prepared.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-13 inhibiting compounds with a benzoxazinone moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13 inhibitors.
Description
CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional Application No. 60 / 905,565, filed Mar. 7, 2007, which is hereby incorporated by reference.FIELD OF THE INVENTION[0002]The present invention relates generally to metalloprotease inhibiting compounds containing a heterocyclic moiety, and more particularly to MMP-13 inhibiting compounds with a benzoxazinone moiety.BACKGROUND OF THE INVENTION[0003]Matrix metalloproteinases (MMPs) and aggrecanases (ADAMTS=a disintegrin and metalloproteinase with thrombospondin motif) are a family of structurally related zinc-containing enzymes that have been reported to mediate the breakdown of connective tissue in normal physiological processes such as embryonic development, reproduction, and tissue remodelling. Over-expression of MMPs and aggrecanases or an imbalance between extracellular matrix synthesis and degradation has been suggested as factors in inflammatory, malignant and degenerative disease p...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More